Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy

In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the w...

Full description

Bibliographic Details

Published in:	The oncologist (Dayton, Ohio) Ohio), 2020-03, Vol.25 (3), p.e398-e404
Main Authors:	Zubiri, Leyre, Allen, Ian M., Taylor, Martin S., Guidon, Amanda C., Chen, Steven T., Schoenfeld, Sara R., Neilan, Tomas G., Sise, Meghan E., Mooradian, Meghan J., Rubin, Krista M., Leaf, Rebecca Karp, Parikh, Aparna R., Faje, Alexander, Gainor, Justin F., Cohen, Justine V., Fintelmann, Florian J., Kohler, Minna J., Dougan, Michael, Reynolds, Kerry L.
Format:	Article
Language:	English
Subjects:	B7-H1 Antigen Combined Modality Therapy Commentaries Humans Immune checkpoint inhibitor Immune Checkpoint Inhibitors Immune‐related adverse events Immunotherapy Immunotherapy toxicity PD‐1/L1 inhibitor Programmed Cell Death 1 Receptor
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!